Is Lymphocytic Bronchiolitis a Marker of Acute Rejection? An Analysis of 2,697 Transbronchial Biopsies After Lung Transplantation

Burton, Christopher M.; Iversen, Martin; Scheike, Thomas H.; Carlsen, Jørn; Andersen, Claus B.

doi:10.1016/j.healun.2008.06.014

Cited by 32 publications

(27 citation statements)

References 19 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another potential BOS phenotype suggested in recent literature consists of recipients with significant bronchoalveolar lavage (BAL) neutrophilia who respond to azithromycin therapy [25,26]; FEV1 may improve such that the recipient no longer meets the spirometric criteria for BOS. These patients appear to have a reversible, BOS-like syndrome associated with BAL neutrophilia, and the recently published, Risk factors associated with the development of BOS Non-minimal (Grade oA2) acute cellular rejection and lymphocytic bronchiolitis Grade A2 or above acute cellular rejection on lung biopsy [28] has been linked to subsequent development of BOS [6,[29][30][31][32][33][34][35][36]. Late acute cellular rejection [30,31,33] and both increasing frequency and severity of acute cellular rejection [6,30,33] have been found to be risk factors for BOS.…”

Section: Bos Phenotypesmentioning

confidence: 99%

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

et al. 2014

View full text Add to dashboard Cite

Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is associated with poor survival. The International Society for Heart and Lung Transplantation, American Thoracic Society, and European Respiratory Society convened a committee of international experts to describe and/or provide recommendations for 1) the definition of BOS, 2) the risk factors for developing BOS, 3) the diagnosis of BOS, and 4) the management and prevention of BOS.A pragmatic evidence synthesis was performed to identify all unique citations related to BOS published from 1980 through to March, 2013. The expert committee discussed the available research evidence upon which the updated definition of BOS, identified risk factors and recommendations are based. The committee followed the GRADE (Grading of Recommendation, Assessment, Development and Evaluation) approach to develop specific clinical recommendations.The term BOS should be used to describe a delayed allograft dysfunction with persistent decline in forced expiratory volume in 1 s that is not caused by other known and potentially reversible causes of posttransplant loss of lung function. The committee formulated specific recommendations about the use of systemic corticosteroids, cyclosporine, tacrolimus, azithromycin and about re-transplantation in patients with suspected and confirmed BOS.The diagnosis of BOS requires the careful exclusion of other post-transplant complications that can cause delayed lung allograft dysfunction, and several risk factors have been identified that have a significant association with the onset of BOS. Currently available therapies have not been proven to result in significant benefit in the prevention or treatment of BOS. Adequately designed and executed randomised controlled trials that properly measure and report all patient-important outcomes are needed to identify optimal therapies for established BOS and effective strategies for its prevention. Executive summaryMany lung transplant recipients develop delayed allograft dysfunction that has been traditionally referred to as bronchiolitis obliterans syndrome (BOS), which is thought to be caused by inflammation, destruction and fibrosis of small airways in the lung allograft that leads to obliterative bronchiolitis (OB). Because a definitive diagnosis of OB is difficult to make without a surgical lung biopsy, a decrease in the forced expiratory volume in 1 s (FEV1) has been used as a surrogate marker to identify patients who develop a syndrome of significant and persistent loss of lung allograft function with onset three or more months following transplantation. However, it is now recognised that numerous factors apart from OB can lead to a delayed onset, significant decline in lung function, and these causes of delayed onset graft dysfunction must be carefully excluded when a diagnosis of BOS is made. In general, BOS responds poorly to therapeutic interventions but may stabilise, and some patients may have a significant improvement in FEV1 with certain ther...

show abstract

Section: Bos Phenotypesmentioning

confidence: 99%

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

et al. 2014

View full text Add to dashboard Cite

show abstract

“…It is remarkable that only 14.5% of the biopsies displayed LAD, while other centers found a positive score in almost 50% of their biopsies (5,17). This could be explained by our clinical routine follow up, as we only take routine biopsies on day 21 and day 90, otherwise only when clinically indicated.…”

Section: Discussionmentioning

confidence: 93%

Lymphocytic Bronchiolitis After Lung Transplantation Is Associated With Daily Changes in Air Pollution

Verleden

Scheers

Nawrot

et al. 2012

American Journal of Transplantation

View full text Add to dashboard Cite

“…15 Infection is well-known to histologically mimic the perivascular inflammation of acute rejection 24,40,41 and LB, 9 and pathologists must remain vigilant in excluding infection as the cause for histologic findings. Unfortunately the exclusion of infection is not always straightforward in the lung transplant population 42,43 ; however, there may be a role for mucosal CD3 immunostaining, which has been shown to be significantly higher in grade B rejection than in infections. 44 This study had several limitations.…”

Section: Discussionmentioning

confidence: 99%

SaLUTaRy: Survey of lung transplant rejection

Gordon

Bhorade

Vigneswaran

et al. 2012

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Is Lymphocytic Bronchiolitis a Marker of Acute Rejection? An Analysis of 2,697 Transbronchial Biopsies After Lung Transplantation

Cited by 32 publications

References 19 publications

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

Lymphocytic Bronchiolitis After Lung Transplantation Is Associated With Daily Changes in Air Pollution

SaLUTaRy: Survey of lung transplant rejection

Contact Info

Product

Resources

About